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Background: Triple-negative breast cancer (TNBC) remains a challenging topic for clinical oncologists. This study
sought to evaluate TNBC versus other breast cancer subtypes with respect to survival parameters. We evaluated
possible differences in survival in TNBC by age and by the extent to which evidence-based treatment guidelines
were adhered.
Methods: This German retrospective multi-center cohort study included 9156 patients with primary breast cancer
recruited from 1992 to 2008.
Results: The rates of guideline adherence are significantly lower in TNBC compared to non-TNBC subtypes. These
lower rates of guideline adherence can be observed in all age groups and are most pronounced in the >65
subgroup [<50 (20.9% vs. 42.0%), 50–64 (25.1% vs. 51.1%), and >65 (38.4% vs. 74.6%)]. In TNBC patients of all age
groups, disease-free survival and overall survival were associated with an improvement by 100% guideline-adherent
adjuvant treatment compared to non-adherence. Furthermore, TNBC patients of all ages had similar outcome
parameters if 100% guideline-adherent adjuvant treatment was applied.
Conclusion: The rates of guideline-adherent treatment were significantly lower in TNBC, even though guideline
adherence was strongly associated with improved survival. In the case of 100% guideline-adherent treatment, no
difference in survival was observed over all the age groups examined, even in the group of >65-year-old TNBC patients.
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Breast cancer comprises a complex and heterogeneous
group of diseases at the clinical, morphological, and mo-
lecular levels [1-6]. Specimens that display basal-like fea-
tures are called “triple-negative” breast cancer (TNBC)
in routine practice because they are defined by their lack
of estrogen receptor, progesterone receptors, and human
epidermal growth factor receptor 2 (Her2). Although
TNBC represents 10-20% of all invasive breast cancers,
it is more frequent in young premenopausal and
African-American patients [7-9]. TNBC is associated* Correspondence: lukas.schwentner@yahoo.de
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distribution, and reproduction in any mediumwith an advanced stage at initial diagnosis, higher grad-
ing, family history, and BRCA mutations [7-9]. Addition-
ally, TNBC patients lack the benefit of routinely
available targeted therapy, which explains the growing
attention of both pathologists and oncologists to an eas-
ily recognizable type of breast cancer with aggressive be-
havior and poor therapeutic options [5].
The prognosis of women with TNBC is significantly
poorer compared to that of women with other subtypes
of breast cancer, and different routes of metastatic
spread may explain the higher recurrence and mortality
rates of TNBC patients. The impact of different therap-
ies is yet not clear because few data from randomized
controlled trials (RCTs) have been published. Although
RCTs are the gold standard of therapy schemes, it is ne-
cessary to compare them with observational data.ntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Inclusion criteria for guideline adherence based on the German national consensus guideline (S3 guideline) for
the decisions regarding loco-regional treatment (surgery and radiotherapy), chemotherapy, and endocrine therapy
Group A – Surgical therapy
Breast conserving therapy (Reference: Statements 7, 8)
Conforming to guideline recommendations Non-conforming to guideline recommendations
BCT in DCIS and LCIS < 4 cm BCT when tumor size > 4 cm
BCT in R0 BCT in R1
BCT in presence of multicentricity
BCT in presence of inflammatory carcinoma
Mastectomy (Reference: Statement 9)
Conforming to guideline recommendations Non-conforming to guideline recommendations
Mastectomy for microcalcification of malignant type No mastectomy in the presence of microcalcification
of malignant type
Mastectomy for intraductal carcinoma and tumor size > 4 cm No mastectomy in the presence of multicentricity
Mastectomy for multicentricity Mastectomy for intraductal carcinoma with a tumor
size < 4 cm
Mastectomy for R1 No mastectomy for inflammatory breast cancer
Mastectomy for inflammatory breast cancer
Axillary dissection (Reference: Statements 12, 13)
Conforming to guideline recommendations Non-conforming to guideline recommendations
Removal of invasive carcinoma + dissection for at least level I
and II + removal of at least 10 lymph nodes
Lymph node removal in non-invasive carcinoma
Invasive carcinoma + (only dissection for level I or
removal of <10 lymph nodes)
Group B – Radiotherapy
Radiotherapy secondary to BCT (Reference: Statements 23, 24)
Conforming to guideline recommendations Non-conforming to guideline recommendations
Radiotherapy secondary to BCT for invasive carcinoma No radiotherapy secondary to BCT for invasive carcinoma
Postmastectomy strategy (Reference: Statements 25, 26)
Conforming to guideline recommendations Non-conforming to guideline recommendations
Radiotherapy secondary to mastectomy and R1/R2 Radiotherapy in mastectomy and R0
Radiotherapy secondary to mastectomy and nodes involved ≥4 Radiotherapy in mastectomy and T = T1 or T2
Radiotherapy T = T3 or T4 No radiotherapy in mastectomy and R1/R2
No radiotherapy in mastectomy and nodes involved ≥4
No radiotherapy in T = T3 or T4
Group C –Endocrine therapy
Endocrine therapy (Reference: Statements 33–37)
Conforming to guideline recommendations Non-conforming to guideline recommendations
Tamoxifen for invasive carcinoma in patients with positive
hormone receptor status
Hormone therapy in receptor-negative patients
GnRH + tamoxifen or GnRH in premenopausal patients with
positive hormone receptor status
Postmenopausal patient and positive hormone receptor status
and tamoxifen or aromatase inhibitor
Endocrine therapy after chemotherapy in positive
receptor status
Tamoxifen for DCIS
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Table 1 Inclusion criteria for guideline adherence based on the German national consensus guideline (S3 guideline) for
the decisions regarding loco-regional treatment (surgery and radiotherapy), chemotherapy, and endocrine therapy
(Continued)
When estrogen receptor (ER) and progesterone receptor (PgR) are negative:
Risk group Chemotherapy Guideline conformity
Low CT performed Overtherapy
No CT performed Guideline conformity
Moderate CMF/EC/AC Undertherapy
FEC/T Guideline conformity
No CT performed Undertherapy
High CMF/EC/AC Undertherapy
FEC/T Guideline conformity
No CT performed Undertherapy
ER and PgR >0 and <6
Risk group Chemotherapy Guideline conformity
Low CT performed Overtherapy
No CT performed Guideline conformity
Moderate
Premenopausal CT performed Guideline conformity
No CT performed Guideline conformity
Postmenopausal CT performed Guideline conformity
No CT performed Undertherapy
High CMF/EC/AC Undertherapy
FEC/T Guideline conformity
No CT performed Undertherapy
ER or PgR ≥6 Chemotherapy Guideline conformity
Risk group
Low CT performed Overtherapy
No CT performed Guideline conformity
Moderate CT performed Guideline conformity
No CT performed Guideline conformity
High CMF/EC/AC Undertherapy
FEC/T Guideline conformity
No CT performed Undertherapy
Risk group classification in the 2008 S3 guideline is according to Goldhirsch et al. [27].
Key: CT, Chemotherapy; CMF, Cyclophosphamide, methotrexate, fluorouracil, EC/AC, Epirubicin, cyclophosphamide/adriamycin, cyclophosphamide, FEC,
Fluorouracil, epirubicin, cyclophosphamide, T, Taxane.
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survival in the TNBC subgroup. Furthermore, it remains
unclear whether internationally validated guidelines are
likely to improve survival in TNBC breast cancer pa-
tients of different age groups. We, therefore, investigated
whether TNBC patients of different age groups benefit
from different strategies of therapy (e.g., surgery, radi-
ation, adjuvant chemotherapy) according to international
evidence-based guidelines. We analyzed the association
between guideline-adherent adjuvant treatment and sur-
vival outcome in TNBC by investigating the impact ofdifferent guideline-adherent therapies on the survival
(OAS and DFS) of TNBC patients in an observational,
retrospective, multicenter-study called “Breast Cancer
Care under Evidence-based Guidelines” (BRENDA).
Methods
In this retrospective, multi-center cohort study, we ana-
lyzed data from 9156 patients with primary breast cancer
diagnosed or treated at the Department of Gynaecology
and Obstetrics at the University of Ulm and 16 partner
clinics (all certified by the German Society of Cancer as
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between 1992 and 2008. A new documentation system
called BRENDA was designed and used for this purpose.
This documentation system included a retrospective chart
review to abstract TNM stage, histological subtype, grad-
ing, lymphatic and vascular invasion, estrogen, progester-
one, and Her2 expression, date of diagnosis, and all
adjuvant therapies. Data on adjuvant therapies, including
surgery (date of surgery, BCT, mastectomy, sentinel-node
biopsy, and axillary lymph node dissection), adjuvant sys-
temic chemotherapy, adjuvant endocrine therapy, and de-
tailed information on administered adjuvant radiotherapy
were also collected. In the follow-up, data on first recur-
rences, secondary primary tumors, and date and cause of
death were obtained. Questionnaires were sent to the phy-
sicians involved in the follow-up care, to local death regis-
trars, and to patients to determine the recurrence and
survival status of the patients. As measures of comorbid-
ity, the American Society of Anesthesiologists (ASA)
Physical Status and the New York Heart Association
(NYHA) cardiac score at the time of surgery were col-
lected for the patients, if available. Furthermore, occur-
rences of myocardial infarction, stroke, and malignant
diseases were recorded.Figure 1 Cohort diagram of the study group.Written informed consent was obtained from all pa-
tients included in this clinical study. The inclusion cri-
terion was histologically confirmed invasive breast
cancer. The exclusion criteria were carcinoma in situ,
primary metastatic disease, bilateral breast cancer, pri-
mary occult disease, phylloides tumor, incomplete
follow-up, unknown Her2 status or hormone receptor
status (HR status), or missing data on variables used as
covariates in the survival analyses. We considered triple-
negative breast cancer as being estrogen receptor- and
progesterone receptor-negative (IRS 0) and Her2 nega-
tive (0, 1+, 2+, and FISH-negative) [10].
The definition of evidence-based guideline-adherent
adjuvant treatment was based on internationally evi-
dence based validated guidelines. Wolters et al. demon-
strated that the treatment recommendations within
international guidelines are identical and differ only
marginally in adjuvant endocrine therapy [11]. We,
therefore, decided to base the definition of guideline-
adherent adjuvant treatment on the German national
consensus guideline (S3 guideline) for the decision of
loco-regional treatment (surgery and radiotherapy),
chemotherapy, and endocrine therapy (only non-TNBC)
[12] unless it was one of the guidelines taken into
Table 2 Baseline characteristics of the study group based
on 8312 non-TNBC patients and 844 TNBC patients included
in the study
Non-TNBC TNBC
8312 (90.8%) 844 (9.2%)
Mean N Mean N p-value
Age (range) 61.2 (22; 97) 8312 57.7 (27; 97) 844 <0.001
Postmenopausal 74.8% 6220 66% 557 <0.001
T 1 55.3% 4600 48.5% 409 <0.001
T 2 36% 2995 41.4% 349
T 3 3.8% 313 5.9% 50
T4 4.9% 404 4.3% 36
Node negative 59.9% 4979 62.6% 528 0.133
1-3 23.8% 1978 20% 169
>3 16.3% 1355 17.4% 147
G 1 9.9% 820 1.4% 12 <0.001
G 2 65.5% 5447 25.4% 214
G 3 24.6% 2045 73.2% 618
ASA Score >3 21.7% 1068 18.3% 94 0.072
NYHA Class > III 3.5% 92 4.0% 12 0.652
Myocardial infarction,
stroke, or TIA
4.2% 230 3.4% 19 0.340
HR negative 5.8% 481 100.0% 844 <0.001
HR IRS 1-5 23.5% 1953 0.0% 0
HR positive 70.7% 5878 0.0% 0
Her2neu positive 17.7% 1468 0.0% 0 <0.001
Endocrine therapy 82.0% 6816 5.6% 47 <0.001
Chemotherapy 43.0% 3575 77.1% 651 <0.001
Mastectomy 29.0% 2414 26.7% 225 0.145
Radiotherapy 79.2% 6579 80.3% 678 0.420
ASA, NYHA, and myocardial infarction/stroke/TIA were available for 4911, 2608,
and 5466 non-TNBC patients and for 513, 297, and 564 TNBC-patients, respectively.
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therapy regimens were retrospectively evaluated con-
cerning their adherence to the S3 guideline. We classi-
fied the adjuvant treatments as surgery, chemotherapy,
and radiotherapy. Omission of any of the suggested
adjuvant treatment or abandonment of any adjuvant
treatment was classified as non-compliance with the
suggested adjuvant therapy, resulting in one ore more
guideline violations (GV) for each patient (see Table 1).
Statistical analysis
Descriptive analyses were first performed. The data are
presented separately for the group of TNBC and the
group of non-TNBC, and the P-values for the compari-
sons between both groups are based on χ2-tests or t-tests;
a P-value of 0.05 (two-tailed test) was considered signifi-
cant. To estimate hazard ratios (HRs) and confidence in-
tervals (CIs), multivariate survival regressions were then
performed using frailty models with a gamma-distributed
random term [13]. The primary endpoints were disease-
free survival (DFS) and overall survival (OAS). All of the
regression models were adjusted for tumor size (4 categor-
ies), grading (3 categories), nodal status (0, 1–3, or 4+
positive nodes), menopausal status (binary), year of diag-
nosis, comorbidities (see below), presence or absence of
information on comorbidities, and age (with the exception
of the analyses that were stratified by age group).
Comorbidities were measured using the scale of the ASA
(ASA 3 or greater), the scale of the NYHA (NYHA class 3
or higher), history of any prior cancers, and history of apo-
plexy, transient ischemic attack (TIA), or myocardial
infarction. Survival function plots were derived from the
survival regression analysis.
Ethical approval
This study and the BRENDA project have been approved
by the Ethics Committee of the University of Ulm, which
coveres all participating breast cancer centers of the
BRENDA network.
Results
The investigated cohort consisted of 10,897 breast can-
cer patients. In total, 1741 patients were excluded after
applying the exclusion criteria: 8 patients had initially
been diagnosed outside of the 1992–2008 time frame or
had an unknown date of death; the TNBC status of 1214
patients was unknown (1163 unknown Her2 status, 51
unknown HR status); guideline conformity could not be
established for 323 patients; and data for the covariates
used in our analyses were missing for the remaining 196
patients. The final cohort consisted of 9156 patients
with histologically confirmed invasive breast cancer (see
Figure 1). In the final cohort, 844 patients (9.2%) had
TNBC [median age: 57.7 (range: 27–97)].Because we employed a multi-center design, we also
compared the different participating centers. In the co-
hort of the university department, the patients were sig-
nificantly younger (59.8 vs. 61.6 years), and G3 was
significantly more common (31.2% vs. 27.3%). However,
HR-positive breast cancers occurred significantly more
often in the university department, and the patients in
the university department showed significantly higher
rates of comorbidities as measured by the ASA and
NYHA score. In the case of TNBC prevalence, we could
not demonstrate a significant difference between the
university department and the participating breast can-
cer centers.
Compared to the remaining individuals (women without
TNBC) (8312 breast cancer patients; 90.8%), the TNBC
subgroup showed a significantly higher grade (P < 0.001),
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frequently received adjuvant chemotherapy (43.0% vs.
77.1%; P < 0.001). The baseline characteristics of the
9156 patients are shown in Table 2. Surprisingly, 22.9%
of the TNBC subgroup did not receive any adjuvant
chemotherapy.
Initially, we attempted to identify the impact of TNBC
on survival parameters and, therefore, compared the
TNBC subgroup with non-TNBC patients. The TNBC
subgroup demonstrated significantly decreased OAS
[HR = 1.92; P < 0.001] and DFS [HR = 1.53; P < 0.001]
values compared to the non-TNBC population (see
Figure 2). Because breast cancer is a complex disease at
the clinical and morphological levels, we also investigated
the differences between different breast cancer phenotypes
(HR+/Her2-, HR+/Her2+, HR-/Her2+). The TNBC sub-
group showed a significant decrease in OAS and DFS
compared to the HR+/Her2- [OAS, HR = 0.42; P < 0.001;
DFS, HR = 0.53; P < 0.001] and HR+/Her2+ breast cancer
subtypes [OAS, HR = 0.48; P < 0.001; DFS, HR = 0.59; P <
0.001]. Compared to HR-/Her2+ breast cancer, only OAS
[HR = 0.69; P = 0.015] showed a significant impairment in
TNBC, whereas DFS [HR = 1.02; P = 0.88] was not signifi-
cantly different (see Figure 2).
Furthermore, we investigated the TNBC patients in
different age groups (<50, 50–64, and ≥65) (see Table 3).
The TNBC patients aged ≥65 showed significantly higherFigure 2 Overall survival (OAS) and disease-free survival (DFS) for TN
groups defined by HR status and Her2 status (adjusted for year of dia
and comorbidity).rates of comorbidities, as measured by ASA (P-value for
the comparison of the three age groups: P < 0.001) and
NYHA (P = 0.030) and of myocardial infarction/stroke/
TIA (P = 0.001). These patients also received chemother-
apy [90.8% (<50), 86.5% (50–64), and 54.7% (≥65)] (P <
0.001) and radiotherapy [86.2%(<50), 88.0% (50–64), and
67.2% (≥65)] (P < 0.001) less often; in contrast, they
underwent mastectomy significantly more often [18.7%
(<50), 21.5% (50–64), and 39.4% (≥65)] (P < 0.001) and
showed significantly more locally advanced (T4) tumors
(P < 0.001) (see Table 2). When comparing the three age
groups, we observed that the patients aged ≥65 had a
significantly worse OAS [HR = 0.31; P < 0.001] and DFS
[HR = 0.42; P < 0.001] compared to the TNBC patients
aged 50–64 (see Figure 3). However, the difference be-
tween TNBC ≥65 and TNBC <50 was not significant for
OAS [HR = 0.56; P = 0.231] or DFS [HR = 0.87; P = 0.732].
Guideline adherence in the TNBC group and TNBC
age subgroups
Guideline adherence was significantly lower in the
TNBC patients compared to the non-TNBC population
(P < 0.001) (see Table 4). Similarly, the TNBC patients
showed a significantly lower guideline adherence (P <
0.001) in all the age groups, even the TNBC patients <50,
who had lower rates of comorbidities than the other
two subgroups (P < 0.001). These differences in guidelineBC (n = 844) versus non-TNBC (n = 8.312) and for TNBC versus the
gnosis, tumor size, grading, nodal status, menopausal status,
Figure 3 Comparison of overall survival (OAS) and disease-free
survival (DFS) among TNBC patients in three age groups (<50
n = 283; 50–64 n = 274; >65 N = 287) (adjusted for year of
diagnosis, tumor size, grading, nodal status, menopausal
status, and comorbidity).
Table 3 Baseline characteristics of the TNBC age
subgroups (<50, 50–64, and ≥65)
TNBC <50 (283) 50-64 (274) ≥65 (287)
Mean Mean Mean p-value
Age (mean, range) 41.9 (27; 50) 57.7 (50; 65) 73.3 (65; 97) <0.001
Postmenopausal 9.9% 88.3% 100.0% <0.001
T 1 58% 47.8% 39.7% <0.001
T 2 34.6% 42% 47.4%
T 3 6.4% 6.2% 5.2%
T 4 1.1% 4% 7.7%
Node negative 66.8% 61.7% 59.2% 0.165
1-3 19.8% 21.2% 19.2%
>3 13.4% 17.2% 21.6%
G 1 0.7% 2.2% 1.4% 0.012
G 2 18.7% 29.2% 28.2%
G 3 80.6% 68.6% 70.4%
ASA Score ≥3 5.5% 13.1% 37.8% <0.001
NYHA Class≥ III 0.9% 4.1% 8.3% 0.030
Myocardial infarction,
stroke, or TIA
0.5% 2.7% 7.1% <0.001
Endocrine therapy 5.7% 6.6% 4.5% 0.573
Chemotherapy 90.8% 86.5% 54.7% <0.001
Mastectomy 18.7% 21.5% 39.4% <0.001
Radiotherapy 86.2% 88.0% 67.2% <0.001
The p-values are based on differences between the reference groups using the
χ2-test and (for age) the t-test.
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rates of guideline violations concerning chemotherapy in
all the TNBC age groups (P < 0.001) (see Table 3). This
deficiency in guideline adherence concerning adjuvant
chemotherapy was most pronounced in the ≥65 TNBC
subgroup (69.3% versus 23.0% chemotherapy guideline
violations) (P < 0.001). All of the other investigated adju-
vant treatment modalities (surgery and radiotherapy) did
not show significant differences between the TNBC and
non-TNBC populations (P > 0.05).
Next we compared the survival of TNBC patients in
the three age groups according to guideline adherence
(one or more guideline violations vs. complete guideline
adherence). In all three age groups, patients treated
according to guidelines had a better OAS and a better
DFS (see Figure 4), and this effect was significant for the
youngest and oldest age groups: OAS in the ≥65 TNBC
subgroup: HR = 2.89 (P = 0.001); DFS: HR = 2.72 (P =
0.001); OAS in the <50 TNBC subgroup: HR = 3.47 (P =
0.001); DFS: HR = 3.20 (P < 0.001); OAS in the 50–64
TNBC subgroup: HR = 1.27 (P = 0.515); DFS: HR = 1.16
(P = 0.633).
We also investigated the differences between the 100%
guideline-treated TNBC patients in those age groups(<50, 50–64, and ≥65). We chose the TNBC ≥65 group
as a reference group and compared it to both the TNBC
50–64 [OAS, HR = 0.76; P = 0.803; DFS, HR = 1.38; P =
0.602] and <50 [OAS, HR = 1.08; P = 0.909; DFS, HR =
1.45; P = 0.331] subgroups. We did not observe a signifi-
cant difference in any outcome parameter by age group
under the condition of 100% guideline-adherent treat-
ment (see Figure 5). However, if we compared all the
100% guideline-adherent TNBC patients with all the
100% guideline-adherent non-TNBC patients, we ob-
served a significantly inferior OAS [HR = 01.84; P =
0.004] and DFS [HR = 1.55; P = 0.012] in the patients
suffering from TNBC.
Discussion
TNBC remains a challenge in breast cancer care for clin-
ical oncologists. Although evidence-based guidelines are
known to be beneficial in the TNBC subtype [14], to our
knowledge, very few investigations have studied the influ-
ence of age on the prognosis of TNBC [15]. Furthermore,
the efficacy of breast cancer guidelines in elderly TNBC
patients has explicitly been investigated to date and has
only been investigated in non-TNBC patients [16,17].
In the present study, we observed significantly inferior
survival parameters in the TNBC cohort and in the differ-
ent age groups of this cohort. The TNBC ≥65 subgroup
Table 4 Number and percentage of guideline violations
(GV) among non-TNBC and TNBC age subgroups (complete
sample, <50, 50–64, and ≥65) stratified for all adjuvant
treatment modalities (surgery, chemotherapy, and
radiotherapy)
All patients Non-TNBC TNBC
N = 8,312 (90.8%) N = 844 (9.2%)
% N % N p-value
≥1 GV 29.8% 2476/8312 56.0% 473/844 <0.001
GV radiotherapy 8.1% 671/8312 10.0% 84/844 0.059
GV surgery 13.2% 1095/8312 13.5% 114/844 0.785
GV chemotherapy 13.4% 1117/8312 46.6% 393/844 <0.001
Patients < 50 Non-TNBC TNBC
N = 1,784 (86.3%) N = 283 (13.7%)
% N % N p-value
≥1 GV 20.9% 372/1784 42.0% 119/283 <0.001
GV radiotherapy 5.0% 90/1784 7.1% 20/283 0.159
GV surgery 15.8% 281/1784 13.8% 39/283 0.395
GV chemotherapy 1.9% 34/1784 30.0% 85/283 <0.001
Patients 50-64 Non-TNBC TNBC
N = 3,046 (91.7%) N = 274 (8.3%)
% N % N p-value
≥1 GV 25.1% 766/3046 51.1% 140/274 <0.001
GV radiotherapy 5.0% 153/3046 6.6% 18/274 0.267
GV surgery 13.8% 420/3046 14.6% 40/274 0.710
GV chemotherapy 9.2% 281/3046 39.8% 109/274 <0.001
Patients ≥65 Non-TNBC TNBC
N = 3,482 (92.4%) N = 287 (7.6%)
% N % N p-value
≥1 GV 38.4% 1338/3482 74.6% 214/287 <0.001
GV radiotherapy 12.3% 428/3482 16.0% 46/287 0.067
GV surgery 11.3% 394/3482 12.2% 35/287 0.652
GV chemotherapy 23.0% 802/3482 69.3% 199/287 <0.001
The p-values are derived from χ2-tests.
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curred significantly more often in the TNBC subgroups,
particularly in the TNBC ≥65 subgroup. However, when
comparing only those TNBC patients who were treated
according to the guidelines, we found no significant differ-
ences in OAS or DFS between the age groups, indicating
that guideline adherence is associated with improved sur-
vival parameters in primary TNBC patients overall differ-
ent age groups. Conversely, the patients who did not
undergo strict guideline-adherent treatment had a signifi-
cant impairment in survival parameters, except for the
50–64 TNBC age group. Significantly higher rates of
guideline violations concerning adjuvant chemotherapy
could be observed in TNBC and it is, therefore, likely that
these are the most important reasons for the inferiorsurvival. Hence, it is most likely that the higher rates of
chemotherapy guideline violations in the ≥65 TNBC pa-
tients contributed to their inferior survival [14,15].
There are several other factors, such as higher rates of
comorbidities, that could explain the inferior survival in
the ≥65 age group. Indeed, there is a clear association
between comorbidities and guideline adherence. Our
study is an observational study, and confounding factors
may have influenced both the treatment options (or
guideline conformity) and survival. We observed a high
percentage of non-guideline-adherent adjuvant treat-
ment (51.1%) in the 50–64 TNBC subgroup, which was
between the percentages of guideline-non-adherent ther-
apy for the other age groups (42.0% for the <50 and
74.6% for ≥65 subgroups). In addition to the higher rates
of comorbidities, the factors that might explain this re-
sult are the relatively low rates of G3 tumors (68.6%) in
the 50–64 TNBC subgroup, the fact that 86.5% of the
50–64 TNBC subgroup received some type of chemo-
therapy (not all guideline-adherent, see Table 2), and the
fact that 61.7% of the 50–64 TNBC subgroup were node
negative. In summary, the 50–64 TNBC subgroup dem-
onstrated a relatively low risk profile (a low rate of G3
and a high rate of node-negative patients) compared to
the other TNBC subgroups, and 86.5% of these patients
received any type of adjuvant chemotherapy; however,
those chemotherapies were not all guideline-conforming
therapies. Clearly, these circumstances lower the effects
of guideline-adherent adjuvant treatment, leading to
non-significant improvement in survival parameters.
Only a few clinical research studies have investigated
the impact of guideline-adherent therapeutic regimens
on clinical outcomes [17-19]. These studies have con-
firmed that there appears to be a strong association
between guideline-adherent treatment and improved sur-
vival, particularly for several subtypes of breast cancer
[20-23]. Although both patient-related and physician-
related factors can preclude guideline-adherent treatment,
comorbidities are probably among the most important of
these factors [24,25]. Indeed, comorbidities are one of the
most important reasons why elderly breast cancer patients
are not able to follow strict guideline-adherent therapy
pathways, which is one of the reasons explaining their
unfavorable outcome. Unfortunately, the present study
cannot completely corroborate the significance of comor-
bidities for guideline adherence, as only NYHA and ASA
scores were recorded. It is therefore necessary to address
this issue in a prospective trial, which reduces con-
founding factors and allows measurement of comor-
bidities in a validated scoring system. Another point to
consider is that some patients are not willing to follow
strict adjuvant treatment pathways, and this factor was
not recorded in this study either. In this specific cohort,
all of the patients are treated in specialized and certified
Figure 4 Overall survival (OAS) and disease-free survival (DFS) for TNBC patients who received (versus those who did not receive)
100% guideline-adherent adjuvant treatment, as stratified by age (<50, 50–64, and ≥65) and adjusted for year of diagnosis, tumor
size, grading, nodal status, menopausal status, and comorbidities.
Figure 5 Overall survival (OAS) and disease-free survival (DFS) for
TNBC patients who received 100% guideline-adherent adjuvant
treatment, as stratified by age (<50 n = 164; 50–64 n = 134; ≥65
n = 73) and adjusted for year of diagnosis, tumor size, grading,
nodal status, menopausal status, and comorbidities.
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http://www.biomedcentral.com/1471-2407/13/487interdisciplinary breast cancer centers for which an inter-
disciplinary tumor board, for example, is a requirement
for certification by the German Cancer Society. Several
other factors influence guideline adherence in breast
cancer, such as education, access to medical resources,
health care services themselves, and an urban vs. rural
location [26]. Hence, in the current retrospective study,
there are confounding factors affecting both the treatment
and outcome parameters. To reduce the effects of these
potentially confounding factors, we controlled our ana-
lyses for the most important prognostic factors (i.e.,
age, affected lymph nodes, grading, hormone receptor
status, menopause status, year of diagnosis, treatment
in a university hospital, tumor size, and comorbidity)
and included a shared frailty term in our survival
regressions.
An important methodological difficulty of the present
study is the retrospective nature of data collection. It is,
therefore, only possible to draw associations between
guideline-adherent treatment and favorable outcome pa-
rameters. Drawing valid causal conclusions concerning
survival parameters would only be appropriate if treat-
ment allocations were randomized and prospective.
However, randomization concerning guideline-adherent
treatment is not viable because we cannot assign
guideline-adherent and non-guideline-adherent thera-
peutic regimens at random to patients.
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In summary, our data suggest that TNBC has an import-
ant impact on survival among breast cancer patients and
remains the most challenging subtype of invasive breast
cancer. Although its incidence in very young breast can-
cer patients is relatively high [7], an age ≥65 is associated
with an unfavorable outcome in TNBC in this analysis.
However, guideline-adherent adjuvant treatment is asso-
ciated with a significant improvement in survival param-
eters in TNBC patients <50 and ≥65 years old. All the
TNBC age groups demonstrated an equally favorable
outcome if guideline-adherent treatment was applied,
even those aged ≥65. Although guideline-adherent adju-
vant treatment significantly improves survival in TNBC,
the survival parameters in guideline-adherent non-
TNBC patients remain significantly better. Accordingly,
there is an urgent need to improve therapeutic strategies
toward following internationally validated evidence-
based guidelines. It is unknown why so many patients
cannot follow a guideline-adherent adjuvant treatment
pathway. Future research to determine why many pa-
tients fail to adhere to therapeutic guidelines may repre-
sent a profitable research area that could result in
improved survival.
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